Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

PURPOSE: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor indiv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Radiat Oncol
Autors principals: Regine, William F., Winter, Kathryn, Abrams, Ross A., Safran, Howard, Kessel, Ivan L., Chen, Yuhchyau, Fugazzi, James A., Donnelly, Eric D., DiPetrillo, Thomas A., Narayan, Samir, Plastaras, John P., Gaur, Rakesh, Delouya, Guila, Suh, John H., Meyer, Joshua E., Haddock, Michael G., Didolkar, Mukund S., Padula, Gilbert D.A., Johnson, David, Hoffman, John P., Crane, Christopher H.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2018
Matèries:
Pancreas Tumor
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000159/
https://ncbi.nlm.nih.gov/pubmed/29904740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2018.01.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars